Cytokinetics, Incorporated (CYTK) Earnings Call Transcript & Summary

November 4, 2020

NASDAQ US Health Care Biotechnology earnings 66 min

Earnings Call Speaker Segments

Diane Weiser

executive
#1

Good afternoon, and thank you for being with us on today's call. Robert Blum, who serves as our President and Chief Executive Officer, is going to begin by summarizing our top line results from GALACTIC-HF along with a look at how the quarter went for us overall. After that, Fady Malik, our EVP of Research and Development, will share his perspective on those top line results, tell us what to expect from the presentations at AHA, and give an update on METEORIC-HF, which is the second Phase III clinical trial of omecamtiv mecarbil. Following him, Stuart Kupfer, our SVP and Chief Medical Officer, will bring us up to speed on recent progress with CK-274, our cardiac myosin inhibitor that is the subject of REDWOOD-HCM, as well as CK-271, our additional cardiac myosin inhibitor; then Robert Wong, our VP and Chief Accounting Officer, will walk through a financial overview for the quarter; and Ching Jaw, our SVP and Chief Financial Officer, will talk about strategic planning and our financial outlook before Robert Blum shares concluding thoughts regarding the company's path forward and the key milestones we expect for the rest of the year. Please be aware that parts of the discussion that follows, including how we answer questions, include statements tied to future events and performance instead of historical facts, and these are forward-looking statements. What actually happens could differ materially from what these forward-looking statements project. More information about factors that might cause our actual results to differ materially from those in these forward-looking statements appears in our SEC filings. We have no obligation to update any forward-looking statements after this call. And with that, I'll hand the call over to Robert.

Robert Blum

executive
#2

Thanks, Diane, and I appreciate all of you being with us on today's call. Let me start with what's happened most recently. Several weeks back, we were happy to share topline findings from GALACTIC-HF, showing that omecamtiv mecarbil met the trial's primary composite efficacy endpoint and produced a statistically significant reduction in the risk of cardiovascular death or heart failure-related events versus placebo among patients receiving standard of care, with a p-value under 0.05. GALACTIC-HF is an international study of more than 8,000 patients at a large scale — the first Phase III trial examining this novel mechanism. And we'll admit it: together with Amgen, we took a big swing with this Phase III outcomes trial and the broader development program for omecamtiv mecarbil. Our aspiration was to hit a home run for heart failure patients by lowering heart failure events, cutting cardiovascular mortality, enhancing quality of life, and boosting patient stamina and endurance. And although the GALACTIC-HF findings may not have matched our loftiest hopes, since they missed the first secondary endpoint of cardiovascular death alone, we think the results, as already communicated, leave us in potential scoring position — we hit the primary efficacy endpoint and showed balanced safety across treatment arms. Given omecamtiv mecarbil's novel mechanism of action and the breadth and scale of GALACTIC-HF, which enrolled patients across 35 countries, including inpatients and outpatients as well as patients well maintained on standard of care, we believe much more remains to be learned from this trial's results, which the presentation of the primary results at next week's AHA scientific sessions will illuminate. Already, GALACTIC-HF has proven to be a highly important clinical trial for heart failure patients and the heart failure community. That's because we now have evidence that boosting contractility can safely improve meaningfully relevant outcomes that matter to physicians, patients, and payers. And naturally, this is a significant result for Cytokinetics and our employees and shareholders — a major event for us, in fact, given more than 15 years committed to the clinical development of omecamtiv mecarbil, and more recently, commercial readiness for the potential launch of our first-in-class cardiac myosin activator. At present, we're immersed in ongoing analyses of GALACTIC-HF data and conversations about potential next steps with Amgen, as well as with members of the trial's academic executive committee. Together, we're continuing prespecified and supplemental analyses suggested by the top line results, getting ready for the late-breaking presentation Dr. John Teerlink will give at AHA, along with other activities to follow. We look forward to being able to discuss these results in greater detail very soon. After Dr. Teerlink's presentation at AHA, Cytokinetics will convene a publicly available investor and media call with Dr. Teerlink and fellow members of the trial's executive committee will examine the findings, considering how great the unmet clinical need is among heart failure patients and how the disease's economic toll keeps rising. As you'd expect, we're limited in what we can share ahead of the AHA presentation, so in a moment Fady will walk through the top line results and frame them within the trial's design. He will also give you an update on where things stand in METEORIC-HF, which is the second Phase III clinical trial for omecamtiv mecarbil. Now to our cardiac myosin inhibitor program. Progress continues, and we expect to move REDWOOD-HCM into cohort 2 by year-end. Just as with heart failure, people who have HCM badly need new treatments that target the contractile dysfunction underlying their condition, and we're pushing forward with urgency on this program right after our licensing agreement with Ji Xing Pharmaceuticals and the royalty arrangements with RTW. Stuart will share further specifics about this program's progress shortly. Last, through the third quarter we kept up readiness work ahead of a possible launch of a Phase III clinical trial of reldesemtiv in ALS patients. As a reminder, we've said a decision about whether to move reldesemtiv into Phase III would come after we reviewed the GALACTIC-HF results, and no such decision has been reached yet — it is still pending. We'll know more about our plans once GALACTIC-HF results are presented at AHA, and also after internal planning and budgeting wrap up and talks take place with our Board later this quarter, as is convenient. With that, I'll hand the call to Fady, who will go deeper into what's new with omecamtiv mecarbil.

Fady Malik

executive
#3

Thank you, Robert. I want to give my appreciation to the R&D teams and to every one of our Cytokinetics colleagues for their dedication to this program throughout the years, and I also want to praise our Amgen counterparts for the way they carried out GALACTIC-HF and for their partnership. As we made public a few weeks back, findings from GALACTIC-HF indicate that therapy using omecamtiv mecarbil met the primary efficacy endpoint and showed a statistically significant impact in lowering the risk, or the composite outcome, of the interval until a heart failure event or cardiovascular death, whichever came first, versus placebo among patients receiving standard of care. A heart failure event was characterized as an urgent clinic visit, a visit to the emergency department, or hospitalization because of worsening heart failure that resulted in treatment intensifications beyond a switch in oral diuretic therapy. For this benefit, the hazard ratio stood at 0.92, with a p-value of 0.025. We did not see any reduction in the secondary endpoint of CV death. Adverse events, among them major ischemic cardiac adverse events, were balanced across treatment arms. Further prespecified and supplemental subgroup analyses are underway and could point to one or more populations where the drug's effect might be greater than in the overall population. Considering the science behind GALACTIC-HF, certain of these subgroups are fairly sizable and, on their own, exceed many contemporary heart failure trials. Let me remind you that we enrolled a broad and heterogeneous patient population, encompassing patients both within and outside of the hospital, with lower blood pressures and reduced kidney function than is customary in many trials that came before GALACTIC-HF; we anticipate the forthcoming presentation that John Teerlink will deliver virtually on November 13 and expect to elaborate ourselves on our — during this initial presentation in the weeks and months ahead. Although the opportunity for omecamtiv mecarbil in light of these top line results could be different and perhaps less broad than we had anticipated, we believe this novel mechanism drug candidate that enhances cardiac contractility may play an important and complementary role alongside other therapies to boost cardiac function and performance as well as to lower heart failure hospitalizations and events; these continue to represent a high unmet clinical and economic need despite the availability of standard of care therapies. We also anticipate learning about the effects of increasing cardiac contractility among patients with heart failure through adding omecamtiv mecarbil to standard of care as is being studied in METEORIC-HF, the second Phase III trial of omecamtiv mecarbil that continued during the third quarter. METEORIC will provide insight into another key aspect aimed at improving the lives of patients with heart failure with reduced ejection fraction, namely exercise capacity. Exercise capacity is recognized by the FDA as appropriate to demonstrate benefits and, together with the efficacy and safety data we've seen so far from GALACTIC-HF, METEORIC-HF may elaborate further on the potential benefit of omecamtiv mecarbil. Throughout this quarter, METEORIC-HF kept up its enrollment across North America, and the pace of sign-ups picked up in the EU over the summer and fall. Every nation taking part in this study is screening patients in close to all of those who end up randomized. We have just gone past the halfway point toward our goal for randomized participants, and we appreciate the efforts of the sites involved for the momentum we recovered once the trial was reopened to enrollment after the earlier pause this year caused by the COVID-19 pandemic. As everyone here is aware, circumstances are still hard to predict, yet we feel positive that METEORIC-HF will keep enrolling at a strong rate in the months ahead, thanks to the measures our sites have put in place. I am happy to report that over this quarter, the data safety and monitoring committee, or DMC, for METEORIC-HF gathered to examine the data collected so far and advised that the trial proceed as planned, with the protocol left untouched; we anticipate finishing enrollment of METEORIC-HF during the first half of 2021. We stay excited about how omecamtiv mecarbil might deliver a new mechanism therapy into the physician's armamentarium for tackling the progression of heart failure; and crucially, cut down the cycle of hospitalizations and rehospitalizations that burden patients' lives and impose significant cost on hospitals and payers. Over the weeks and months ahead, we will look at next steps alongside Amgen, and we continue to hold the view that boosting cardiac contractility with omecamtiv mecarbil constitutes a novel approach that complements standard of care therapy when managing patients who remain at risk even with standard of care therapies; and at this point I will hand things over to Stuart for an update on our cardiac myosin inhibitor program.

Stuart Kupfer

executive
#4

Appreciate that, Fady. I'd like to begin by giving you the latest on our REDWOOD-HCM Phase II study of CK-274, which is being tested in people who have obstructive hypertrophic cardiomyopathy. I'm happy to share that enrollment for Cohort 1, as well as for REDWOOD-HCM overall, wrapped up in October. As a quick refresher on how the trial is structured...

Diane Weiser

executive
#5

Apologies for cutting in, Stuart. My guess is we should let Fady take it from here. Your line appears to have a lot of static. Fady?

Fady Malik

executive
#6

Let's begin. I want to start with news about REDWOOD-HCM, which is the Phase II study we're running with CK-274 in people suffering from obstructive hypertrophic cardiomyopathy. I'm pleased to report that we wrapped up enrollment for Cohort 1 of REDWOOD-HCM during October. To jog your memory on the study's structure: participants are assigned by chance in a blinded fashion, in a 2:1 ratio, to receive either placebo or escalating doses of CK-274. For cohort 1, the amounts given each day are 5, 10, or 15 milligrams, and how the dose is adjusted upward depends on each individual patient reaching particular echocardiographic goals. The course of treatment runs for ten weeks, and it's designed to help us assess safety and tolerability along with pharmacokinetic and pharmacodynamic responses. We anticipate that the last patient will complete dosing during Q4, and that will guide our decision to advance into Cohort 2 before the year is out, with full data expected by the middle of 2021. Our setup has us ready to launch Cohort 2, since the majority of sites are up and running throughout North America as well as major European nations such as Spain, the Netherlands and Italy. There's still a lot of interest from researchers and study groups in joining this trial so they can help define the benefit/risk picture for our cardiac myosin inhibitor, which is next-in-class, and we're excited to keep working with them. Regarding what you'll hear from us as we move Cohort 2 forward: since the study will still be running and we won't have fully unblinded the treatment assignments, our plan is to share which doses were chosen for Cohort 2, drawing on what we learned in Cohort 1, and maybe some sense of the overall direction of the data. At the end of the day, what REDWOOD-HCM is trying to accomplish is figuring out the best way to dose CK-274 for a Phase III study. That decision will rest on how the drug behaves pharmacodynamically—things like easing the blockage in the left ventricular outflow tract—along with how safe and tolerable CK-274 turns out to be. We still intend to launch a Phase III registration program for CK-274 in obstructive hypertrophic cardiomyopathy patients in late 2021. One thing I'm happy to share is that the REDWOOD-HCM data monitoring committee held a meeting this quarter. After looking over the data collected so far, the committee advised that the study keep going as planned, with the protocol left untouched. We also moved things forward this quarter with our new collaborators at Ji Xing Pharmaceuticals. We're getting things lined up so that clinical development of CK-274 can begin in China, which would let that country take part in the pivotal Phase III trial. Our thinking is that having patients from China enrolled in a possible international registration study could bring important benefits to a potential global registration program for CK-274. At the same time, Cytokinetics kept working during the quarter on plans for running trials of CK-274 in indications that might include nonobstructive hypertrophic cardiomyopathy as well as the subgroup of heart failure patients with preserved ejection fraction, or HFpEF. We're eager to say more about what we may have planned for CK-274 in these areas during 2021. Also in the quarter, we kicked off a Phase I trial for CK-271, which is another one of our cardiac myosin inhibitors. As a reminder, this first-in-human Phase I study is primarily designed to assess the safety and tolerability of CK-271, as well as its pharmacokinetics, when administered as single ascending oral doses in healthy adults. That study is still on track to be completed during the fourth quarter. Additionally, during the quarter, we were pleased to award a $1 million grant and launch a 4-year collaboration with the HCM registry — a global database of hypertrophic cardiomyopathy patients focused on improving predictive risk measures for complications and identifying biomarkers associated with adverse clinical outcomes. Funding for that registry up to now has come from the National Heart, Lung and Blood Institute, which is part of the National Institutes of Health. It's being run by the University of Virginia together with the University of Oxford. Cytokinetics, as an industry sponsor, will participate on the HCM Steering Committee in an observational role. This long-term dedication to such a significant effort matches our commitment to outcomes research and our own drug development, all in service of patient-centric engagement and extending health span; with that, I'll hand things to Robert Wong, who'll give an update on our financials. Robert?

Robert Wong

executive
#7

Appreciate that, Fady. To start, I'll give you an update on where we stand with cash, revenue, and spending, and after that Ching will walk through our strategic planning and the financial picture going forward. If you want more detail on how we actually performed in the third quarter, it's all in the press release we put out earlier this afternoon. When the third quarter closed, we had roughly $451 million in cash and investments. That figure leaves out $85 million, which we anticipate receiving when the sale closes of a royalty on mavacamten, MyoKardia's drug, to RTW Investments. Most of what we brought in during Q3 2020 came from license revenue tied to the RTW transaction, along with our strategic alliances with Amgen and Astellas. R&D expenses for the third quarter of 2020 rose to $24.2 million, compared with $20.2 million in the same period of 2019, largely driven by greater spending on activities tied to REDWOOD-HCM and on readiness work for a possible Phase III trial of reldesemtiv. As we anticipated, over 50% of those R&D expenses stemmed from our cardiovascular program, reflecting activity around METEORIC-HF and the cardiac myosin inhibitor program. The rest of our expenses came mainly from our early research work. G&A expenses for the third quarter of 2020 reached $12.3 million, an increase from $9.8 million in Q3 2019, mostly because of higher personnel-related costs, stock-based compensation among them. With that, Ching will now go over our strategic planning and cash runway through year-end.

Ching Jaw

executive
#8

Thanks, Robert. As we've mentioned before, each summer we run a strategic planning effort so that we're ready to present to and discuss with our Board in early September; when it came to 2020, our strategic plan centered on scenario planning around possible GALACTIC-HF outcomes. What GALACTIC-HF ultimately showed matched one of those scenarios we'd talked over with our Board, and I'm happy to report that an operational plan exists to carry the program and the company forward. Along with our partner Amgen, we'll keep analyzing the data and will refine that operational plan so the right resources get allocated to back the potential plans for omecamtiv mecarbil at the proper moment. Heading toward year-end, several transactions we closed this summer leave us financially strong. Through this set of licensing, royalty monetization and equity financing deals, we now have plenty of cash runway to get ready for possible commercialization of omecamtiv mecarbil, to push ahead with the development plan for CK-274, and potentially to run a Phase III clinical trial of reldesemtiv in patients with ALS — a decision that hasn't been made yet and will come after ongoing discussions later this quarter. As a reminder, we completed a series of transactions with affiliates of RTW Investments LP, and Ji Xing Pharmaceuticals Limited tied to CK-274, under which Cytokinetics will get a mix of committed capital funding and sales proceeds of up to $250 million and can receive as much as $200 million in milestone payments plus royalties on future sales of CK-274 in certain Asian countries; we also brought in $189 million in net proceeds from an underwritten public offering in July. To recap our cash position, the third quarter closed with $451 million in cash, and we now expect to finish 2020 with over $500 million in cash plus committed cash subject to closing conditions of the royalty monetization portion of the RTW transaction; we believe that cash balance will then equal at least 3 years of forward cash according to our 2020 spending. On top of that, we can draw an additional $90 million at our option for further development of CK-274 per the RTW transaction. True to our practice, we'll give 2021 guidance alongside our Q4 earnings in early 2021, aiming to deploy capital prudently as we execute our Vision 2025 and close the year with more than 3 years of forward cash. With that, I'll hand the call back to Robert Blum.

Robert Blum

executive
#9

Appreciate that, Ching. I want to wrap up this call where I began it. Specifically, we're very pleased that we recently shared results from GALACTIC-HF — the first extensive Phase III study to demonstrate that, compared with placebo, omecamtiv mecarbil reduced the likelihood of the combined endpoint of cardiovascular death or heart failure-related events in patients receiving standard of care, achieving a p-value below 0.05. We think this marks a major milestone for everyone dealing with heart failure, and for Cytokinetics as well; in our view, data from a landmark trial demonstrated that our cardiac myosin activator improves how the heart performs and functions while lowering associated clinical events, and side effects were comparable across the treatment groups. Because of that, we believe it may offer doctors and the people they treat a valuable new option for handling both the clinical and financial toll of heart failure, and we're eager for further findings to be presented at AHA. At present, we are in discussions with Amgen about what to do next. We might also sit down with clinical specialists, and those conversations could shape how we go on to do market research, health economics and outcomes research, plus other commercial analyses — all of which might help clarify a possible route ahead. As we learn more, we're eager to pass it along. Fady already walked you through where things stand with our cardiac myosin inhibitor, so I'll skip going over it again. On the neuromuscular side, though, as was mentioned today, during Q3 we kept up some preparatory work so that we could potentially launch a Phase III trial of reldesemtiv in ALS patients. Our position has been that whether we move ahead hinges on how things shake out with GALACTIC-HF and on our cost of capital at that moment. With clearer visibility now, the leadership team is internally weighing the next steps, along with our Board, aiming to settle the question of whether to move forward before the year is out. To wrap up, in the quarter just passed, we showed once more how Cytokinetics stands behind the patient populations it works for: we extended our collaboration with Cure SMA, aimed at growing education, awareness, public policy and fundraising efforts around spinal muscular atrophy, and we also introduced the third annual Cytokinetics Communications Fellowship Grant Program, which is meant to help build greater capacity in communications, awareness building and community engagement across heart failure, HCM, ALS and SMA too. All things considered, as we head into the last stretch of 2020, we remain dedicated and hopeful about our diversified pipeline, our research portfolio and our commercial prospects. At this point, allow me to go over the milestones we expect for what's left of 2020. Regarding omecamtiv mecarbil, data from GALACTIC-HF should be shared during a late-breaking clinical trial slot at the AHA scientific sessions, which take place next week in this fourth quarter. Enrollment for METEORIC-HF, in patients suffering heart failure, ought to wrap up during the first half of 2021. As for AMG 594, talks with Amgen about the development program's next steps are set to carry on. With CK-274, we anticipate having results from Cohort 1 of REDWOOD-HCM by the close of 2020, which will guide whether this Phase II clinical trial moves forward into a second cohort. Turning to CK-271, the Phase I study should finish in this year's fourth quarter. For reldesemtiv, preparations will keep going for a possible Phase III clinical trial plus registration program among ALS patients. On our ongoing research, work aimed at the cardiac and skeletal sarcomere, along with our other muscle biology research programs, is expected to proceed, and collaboration with Astellas on finding next-generation skeletal sarcomere muscle activators should also continue through the close of this year, 2020. Operator, given all that, let's go ahead and open the call for questions.

Salim Syed

analyst
#10

I’ve got 3, if that’s okay: 2 about omecamtiv and 1 about CK-274. Robert, you said you’re potentially in a scoring position for omecamtiv. So I’m wondering whether you’ve actually met with the FDA or provided the data to them. And are there any gating factors when it comes to filing a regulatory application for approval there? Then a couple for Fady. Fady, I realize you can’t comment on the data we’ll receive at AHA. But in theory, is there anything in the mechanism that might tell us something about the inpatient population—why this drug could work better in inpatients than outpatients, which would be the reverse of what showed up in the PARADIGM and DAPA trials? And then one about CK-274. Could you clarify whether we’ll get LVOT gradient data for Cohort 1?

Robert Blum

executive
#11

Good questions. I’ll take the first one. No, we have not had interactions with regulatory authorities. Amgen and we have a great deal of work to do analyzing the data so we can understand the path forward. Having those kinds of discussions now would be premature. Fady, would you like to take the next two?

Fady Malik

executive
#12

Absolutely, I'll handle the following one. As for what you asked about inpatient and outpatient groups, we really haven't indicated any particular trend in those 2 subgroups. That information is going to be shared at AHA. I'm not able to say much more about it; when it comes to CK-274, we won't necessarily share numerical data on the LVOT gradient, though we might talk about some general direction there. Keep in mind, the first cohort is only beginning at the lower doses, and its purpose is to show us what the smallest starting dose should be. So clearly, we don't anticipate hitting the highest pharmacodynamic effects in that initial group. Therefore, I believe more suitable quantitative data will have to wait until the study is finished.

Dane Leone

analyst
#13

Thanks for the updates. First, I'd like to just sort of get some clarity, since the line was dropping out a bit when REDWOOD came up at the beginning. So, just so everyone's on the same page, the first cohort has completed enrollment. And when will the final patient reach 10 weeks of follow-up? Is that what you'd wait for before you discuss or begin enrolling patients into Cohort 2? And then what's your expectation for enrollment in Cohort 2? I know you're going over some of this again, but parts of it were hard to hear.

Fady Malik

executive
#14

Yes. Like I mentioned, we finished enrolling Cohort 1 right at the start of the quarter, so we'd anticipate that every patient will have gotten through 10 weeks before the year is over. For the second cohort, we think enrollment should go much more quickly. We have all this — we have far more sites up and running; they'll be able to prescreen patients and get them, ideally, into a range for their visits and such. COVID-19 is still an unpredictable factor. But thus far, I believe sites are well prepared, and hopefully, we'll see them remain open throughout the winter months. The data that guide the move from Cohort 1 to Cohort 2 won't necessarily cover every last patient in Cohort 1, but will cover a substantial portion of them, enough for us to determine doses for the next group.

Robert Blum

executive
#15

Now, regarding what Dane mentioned about cohort number two — I should point out that while enrollment was paused, Fady and the people working with him managed to bring a large number of additional sites into the study. As a result, the count of sites actively putting patients into the trial should now exceed the number of patients required for every cohort. Because of that, we anticipate cohort two will fill up at a much quicker pace compared to cohort one.

Dane Leone

analyst
#16

All right. I appreciate the clarification. I have one more question about that same subject. Regarding the data — so you won't be blinded to whatever data informs how the second cohort begins. You simply aren't going to, I guess, talk about it at a granular level or — apologies, I was attempting to grasp that remark in terms of what — regarding how unblinding functions between Cohort 1 and afterward transitioning to Cohort 2?

Fady Malik

executive
#17

Correct. Our teams won't have patient level data unblinded. What we'll get are summaries of aggregate data, allowing us to examine how the drug affects ejection fraction, how it affects left ventricular outflow gradient, and adverse events as they might have happened during the trial. That's going to assist us in determining which doses we intend to plan for Cohort 2. Unblinded data will be available to the data monitoring committee; though clearly, they'll review it in confidence, and they'll validate the dose selection that the blinded analysis indicates. I hope that's helpful.

Dane Leone

analyst
#18

Yeah. Apologies — that's probably a silly thing to ask. Once Cohort 1 finishes 10 weeks of dosing, what's the reason it has to remain blinded?

Fady Malik

executive
#19

The reason it remains blinded is that the trial clearly isn't finished yet. The placebo arm from Cohort 1 will be pooled together with the placebo arm from Cohort 2, creating one combined placebo group. So keep in mind, randomization in this trial is 2:1. That means 12 patients receiving CK-274 and 6 receiving placebo in Cohort 1, then an additional 12 on active drug and an additional 6 on placebo in Cohort 2. When you pool those 2 groups, you end up with 12 placebo patients, 12 active patients at the lower doses, and 12 active patients at the higher doses. And our view is simply that keeping individual patient drug assignments blinded until the whole study is finished and unblinded makes for better trial conduct.

Dane Leone

analyst
#20

All right. So basically, for Cohort 1, the information you'd be talking about either before or near the end of the year — would that be a combined dataset covering every patient, whether on placebo and/or the active drug? Or did you mean something more like top-line information for just the group receiving active treatment? That's the part that leaves me somewhat unclear.

Fady Malik

executive
#21

Yeah. Dane, I believe — we haven't laid eyes on those results at all, so I'd rather not dive into specifics about precisely what we plan to put together for a press release. What I — the comments we provided simply indicate a sense of direction. Was there an observation that the LVOT gradient began to go down? Were there individuals whose drug was stopped because of EF under 50, that sort of thing. I doubt we'll be sharing particular figures, since the data will still be blinded. The proper comparator — namely the pooled placebo arm — won't be available to us. For example, you cannot derive a placebo-corrected change from baseline without having that placebo arm.

Dane Leone

analyst
#22

Understood. However, wouldn't the information you're referring to pertain to the treatment arm rather than those receiving placebo? I'm merely attempting to clarify if those got combined in your description.

Fady Malik

executive
#23

Presumably, what we'll report is the data we believe come from the treated group. That is accurate.

Pete Stavropoulos

analyst
#24

Pete Stavropoulos here, filling in for Charles. Nice work on the GALACTIC study and everything you accomplished during the quarter. I have a few questions. Could you walk us through who the patients in METEORIC are? How does that group stack up against the one in GALACTIC? And in what ways might this trial assist in setting ome apart from competing drugs in this area?

Robert Blum

executive
#25

Those are good questions. So the people being enrolled in METEORIC are outpatients, and they aren't thought to carry the same level of risk, since they haven't been hospitalized because of a diagnosis of acute heart failure within 1 year, which was what the inclusion criteria for GALACTIC demanded. That makes them a more stable outpatient group; naturally, they also need to be capable of completing an exercise protocol. So compared with some patients in the GALACTIC trial, they may not be as high-risk, or they may be lower risk, but even so, these individuals have heart failure along with low ejection fraction and systolic dysfunction. Now, what was that second question again?

Pete Stavropoulos

analyst
#26

In what ways could it be useful for setting ome apart from the other drugs in this area?

Robert Blum

executive
#27

Yes. That is a very good question. When we were getting ready for this Phase III clinical trials program — we at Cytokinetics, working alongside Amgen — we considered how we might distinguish ourselves both from standard of care and from potential new medicines that were on the horizon. And it would truly be a distinguishing feature if we had a drug that was boosting cardiac performance and function while also extending time to exercise fatigue or increasing endurance and stamina. At present, there aren't part failure drugs capable of doing that, and for a new medicine in heart failure that would be a meaningful distinguishing feature. So that is why we set about doing both a large outcomes trial and this trial of METEORIC. And we look forward to the results from METEORIC next year.

Pete Stavropoulos

analyst
#28

All right, and I have one additional item regarding the GALACTIC findings. What's the right way for us to consider the decrease in risk that was seen compared with other heart failure trials conducted lately? Also, do you think it might be able to hold its own against competitors in this area?

Robert Blum

executive
#29

That's a hard one to respond to when you haven't yet been shown the complete data, which will be coming your way at AHA next week. Still, I'd urge some caution before assuming these drugs can simply be swapped for one another, since their mechanisms differ and the study designs differ too. It truly isn't a comparison of like with like. I suppose the folks on Wall Street want to rank them side by side, yet I doubt that's really workable, particularly with the unmet need that remains under standard of care. So once the data has been presented next week, I believe we'll be able to address what you've asked in a somewhat more useful way.

Pete Stavropoulos

analyst
#30

Okay, and is there any possibility in your view that COVID played a role in shaping those figures for the secondary endpoint in Q1?

Robert Blum

executive
#31

At this point, nothing leads us to suspect that. Naturally, though, further analyses are still underway. Still, based on what we currently know, I don't see it having played any part.

Hannah Latimer

analyst
#32

Hi, it's Hannah. I only have a couple of quick questions. What's your view on the possibility of submitting for conducting extra trials...

Diane Weiser

executive
#33

Hannah, we can barely make out what you're saying. Your line has a great deal of static.

Robert Blum

executive
#34

Let me make sure I've got this right — you're asking about our capacity to submit a filing that relies on GALACTIC, as opposed to holding off until we have data from a different study? Is that an accurate reading of your question?

Hannah Latimer

analyst
#35

Right, got it.

Robert Blum

executive
#36

Honestly, bringing up filing strategies or anything along those lines feels far too early at this point. We need to finish the analyses, and we need to go over these matters with Amgen. Next week you'll get a closer look at these results; and honestly, additional analyses will continue to come afterward, along with other activities. And in my view, any discussion regarding regulatory strategy ought to rest on considerably more work that remains to be completed.

Hannah Latimer

analyst
#37

All right, so has any GALACTIC information been made available to KOLs yet? And has any preliminary reaction come back from them?

Fady Malik

executive
#38

Well, the investigators...

Diane Weiser

executive
#39

Are you asking about — I'm sorry.

Fady Malik

executive
#40

I believe I get what you're asking, Diane. You wanted to know whether we've provided information to the investigators and whether they've given us anything back. No is the answer. Broadly speaking, that hasn't happened on our end so far. Once the AHA investigators are involved, a series of interactions is going to follow.

Jason Butler

analyst
#41

Robert, two things, quickly. To start with, could you refresh our memory on what you're on the hook to spend on omecamtiv between now and when it gets approved? Then second, regarding AMG 594, remind us — what were you originally aiming to find out from that Phase I trial, the PK/PD parameters? And how is that shaping the picture of what pharmacological attributes the product in this program could have, and as a result, which indications might potentially be read on?

Robert Blum

executive
#42

On the first one, about the costs we might be taking on for omecamtiv, I'll have Ching address that. Then for the second, perhaps I'll turn it over to Fady.

Ching Jaw

executive
#43

Yes. Jason, what you're bringing up, I believe, is how the METEORIC trial is being run. Under the terms of that agreement, Amgen covers the entire out-of-pocket expense, while Amgen and Cytokinetics each put up 50% of the FTE-related costs. That's what the agreement specifies.

Fady Malik

executive
#44

And Jason, I'm sorry, could you repeat your second question?

Jason Butler

analyst
#45

Yeah. So, Fady, regarding 594, what are you expecting to find out from the Phase I study? What's your thinking on this compound's pharmacology? And how might that translate to possible indications?

Fady Malik

executive
#46

Yeah. For the Phase I program, our goal is to examine the pharmacodynamic effect as dosing goes up and then compare it against observations we've had with omecamtiv mecarbil. So do any pharmacodynamic distinctions exist? Based on the preclinical profile we've generated, we think they do, though assembling the full picture requires a reasonably thorough and careful Phase I trial. What we're aiming to achieve, then, is an understanding of how these might be differentiated. And after that, whether that serves as a rationale for pushing 594 forward into indications distinct from those where omecamtiv mecarbil might be used.

Emanuela Branchetti

analyst
#47

This has come up before, yet I'll attempt to frame it another way. Obviously, you're unable to reveal the data, I realize that. There's plenty of detail regarding what we'll be seeing at AHA; perhaps, though, you could offer some additional color, or at least attempt to, about how you picture the way forward for omecamtiv — that is, we may see results indicating variations across differing patient populations. I'm curious whether any such situations might call for further trials involving omecamtiv, should that even be a possibility. Plus, in light of what will be shown at the AHA, how ought we to view METEORIC's significance?

Robert Blum

executive
#48

I do appreciate the effort to pose your question differently, yet I doubt I can deliver a substantially different response. Having this discussion once the results are out would be preferable, since then we could speak more openly regarding what the data indicate. Still, bear in mind that GALACTIC involves a clinical trial of 8,000 patients. Our baseline characteristics publication already exists, and it reveals much about heart failure — including where substantial unmet need persists and where omecamtiv mecarbil might produce varying effects across different large prespecified subgroups; thus, much remains to be discovered and considerable effort lies ahead before we can grasp what the subsequent steps might be. Moreover, we intend to honor our obligations to Amgen by holding those conversations jointly and jointly determining what the following step ought to be. So I'm sorry. I don't believe I can improve on that; still, I hope you see my position, and let's revisit this topic at a later point.

Emanuela Branchetti

analyst
#49

Yes, of course, that makes sense. Just so I have it straight — you said there would be a call following the AHA presentation. I want to make sure I got that right. Will that call happen on the same day as the AHA presentation, or is it scheduled for later on?

Robert Blum

executive
#50

Diane, would you like to handle that?

Diane Weiser

executive
#51

Absolutely, it will fall on that same date. Tomorrow, in fact, we'll be sharing what those specifics are. It's going to come after the presentation given by Dr. Teerlink, though. Any embargo requirements mean we need to work within them. Therefore, it should happen right after his data presentation at AHA. So, the 13th is when it lands.

Edward Tenthoff

analyst
#52

Since most people have been asking about the cardiovascular area, I'll pose 1 regarding the muscle side; could you provide a bit more insight into what factors shape the choice about whether to move forward with reldesemtiv? The reason I'm asking is that it appears to me the main gating considerations ought to be whether or not the data are supportive, and this is a drug. And if that's the case, then pursuing it seems worthwhile. So I want to confirm I grasp roughly how you're framing or ranking that choice?

Robert Blum

executive
#53

That's a good question, Ted. And you're correct. To be clear, as we've stated multiple times, our top priority is to prepare for the possible commercialization of omecamtiv mecarbil. Our next priority is to run development programs, plural, with CK-274 so that we ensure we build on the opportunity there in HCM along with other indications. And then we must ensure we can complete what we begin if we were to move ahead with reldesemtiv. So we devoted the majority of the year to examining the data from the Phase II study, holding discussions with FDA and EMA, engaging with HTAs in Europe and payers, performing a large amount of market research and other activities; we needed to renegotiate our arrangement with Astellas so we could grasp what their commitment and funding would be. And we needed to talk with academics about what a possible Phase III trial serving as registration might look like and discuss that with FDA and EMA; so that requires time. And all of that matters in addition to what the Phase II data show us about a path forward in Phase III. All of it comes together regarding our capacity to run an affordable trial and also ensure it isn't taking away from the other things we're doing; and those are discussions we still must complete internally and with our Board. But we'll reach that point, and we'll do so this quarter. And we want to understand far better our cost of capital, and that will partly be shaped by how we might proceed concerning omecamtiv mecarbil, given what we know from GALACTIC; so all those elements combined, I hope you see. The trial itself, if we were to conduct it, is one that would be perhaps in the range of $35 million to $40 million as would be run over a couple of years, so amortized across a couple of years. And we've already noted that Astellas would fund about 1/3 of that. So the trial wouldn't be all that costly compared with our current operating burn, but we still must ensure it doesn't take away from the other things we need to be prioritizing too. I hope that addresses what you were asking. Is that useful?

Edward Tenthoff

analyst
#54

Very much, Robert.

Robert Blum

executive
#55

Graig, are you there?

Graig Suvannavejh

analyst
#56

Yeah, my apologies for that. Nice work on the momentum you've built. If I may, a handful of questions. I completely understand we still need the AHA data, and that's arriving fairly soon. What I'm wondering is — two things, really. First, have you gotten the chance to go over the data with Amgen? Or will that only occur after it's presented at AHA? And on follow-up, regarding how you'll communicate to the market what comes next, whether that's on the regulatory side or the commercial side, when should we look for that kind of update? Might that be something in the first half of '21? Or is it something by year-end? I'll leave it there for that question.

Robert Blum

executive
#57

Yes. We've held a great many meetings with Amgen, though those have centered on the data. Numerous prespecified analyses are underway, and working through them shapes additional supplemental analyses that are likewise being produced and given priority. So our discussions with Amgen are tightly centered on making sense of the GALACTIC results. Everything else you're bringing up would need to come afterward, and truly can't begin until we've gotten our arms around the data and developed a feel for how the heart failure community might receive it, beginning with AHA next week. Beyond that, clearly there would need to be a good deal of market research plus the other HEOR and additional analyses I referenced in my prepared remarks. So at this point it's difficult to predict whether that means weeks or months, or whether it lands this year or next year. All I'd ask is that you let us keep working on these efforts alongside our partners at Amgen, and we'll provide clarity as soon as we have it.

Graig Suvannavejh

analyst
#58

For my follow-up, I want to focus on what we know so far regarding GALACTIC, including the primary endpoint results and those from the secondary endpoints. First, how should we be evaluating a drug that has this kind of profile? Both your team and Amgen deserve recognition for taking a bold swing with this trial; yet with the profile we have in hand, and again, while we don't yet know the complete picture that AHA will provide, in the absence of a mortality benefit, my question is this: how are you viewing that commercial possibility compared with a scenario where a mortality benefit did exist? Secondly, have you conducted market research with payers, specifically around how they assess value, and how a drug such as omecamtiv would be viewed from a payer standpoint, regardless of whether it offers a novel mechanism of action, or perhaps that factor needs to be taken into account? What's your sense of how payers would approach this? From KOL feedback, I believe we've heard that securing reimbursement can sometimes be challenging for drugs that go beyond what's considered the triple regimen gold standard?

Robert Blum

executive
#59

Yes. So it's a good question. Obviously, things are shifting rapidly in heart failure, and patients now have access to new therapies. Still, every one of those medications acts via its own pathway and was studied in separate clinical trials. Even with those options available, the gap between what patients need and what they're getting remains substantial. The illness and death tied to this condition exceed what you see with most forms of cancer, and that creates both a serious medical shortfall and an enormous financial burden—one that costs Medicare and other insurers a tremendous amount. So judging from the results we've already announced at the top line, it's evident we've got a product with a solid safety profile. So what we've got is a drug candidate that boosts how well the heart works and performs, and it also tackled and brought down outcomes that matter clinically. Sure, it didn't move the needle on cardiovascular death by itself — that part is fair to acknowledge — but figuring out which patients gained the most and which maybe gained the least is going to matter a lot. With 8,000 people enrolled, there's plenty of room to dig into that through prespecified subgroups. And that's really the point where doctors and those paying for care may start looking at drugs built on a new mechanism. Take VICTORIA-HF — Merck and Bayer are pretty optimistic about what vericiguat could do, since that trial showed meaningful clinical drops in outcomes, similar to what we've already announced at the top line, except this was in outpatients whose condition was getting worse. The FDA will give that drug a priority review, and a PDUFA date lands in Q1. Developments of that sort will shape, in the end, the way the heart failure armamentarium keeps changing. Given how much unmet need exists, plus a sizable economic burden, my expectation is that these various medicines will each find a place, sitting side by side and complementing one another. And you're correct that not every one of them is going to serve as foundational care for every patient, yet there are subgroups and cohorts of real importance that are poorly served; that's the space where I'd propose that after we're able to share our results and complete the work we need to do, having that conversation later on might turn out to be productive.

Graig Suvannavejh

analyst
#60

Could I fit in a final question regarding REDWOOD? You may have already addressed it, so I apologize if I overlooked that. What would count as the bar for success? What would seem favorable when it comes to the REDWOOD data?

Robert Blum

executive
#61

Fady, would you like to handle that one? What would seem favorable when it comes to the REDWOOD data?

Fady Malik

executive
#62

I'm not able to do that, but Stuart is available, so perhaps he could handle it — Stuart, did you get your audio issue fixed? Let me give it a shot then; so, what I'd anticipate from the initial set of patients, ideally, is that we start observing decreases in their left ventricular outflow gradient, along with confirmation that the drug is well tolerated. That's essentially the full extent of what you can look for from the first dosing group in a trial built to include a lower dose cohort and a higher dose cohort; and clearly, the second cohort, along with the doses we choose as final doses for Phase III, will shape how we move forward into Phase III.

Gil Blum

analyst
#63

This is Gil speaking instead of Chad. I apologize if I end up asking something you've already covered; it's gotten somewhat late. To start, I'm not sure whether you've discussed possible subgroup analyses. Might we expect to see any region-by-region evaluations of the GALACTIC-HF population? We've lately come across some odd-looking results from other trials showing markedly divergent outcomes between U.S. and ex U.S. patients.

Fady Malik

executive
#64

Yes. Those fall under the prespecified subgroups. So that information is going to be presented.

Gil Blum

analyst
#65

Great. And as a bit of a follow-up to that. Given the way the GALACTIC top line looks, do you think this places greater weight on the data that METEORIC is going to produce? And in what way will the METEORIC data shape possible further development and give us some sense of how omecamtiv works?

Fady Malik

executive
#66

Enrollment in METEORIC will not wrap up until some point in the first half of next year, and the trial itself will not actually be done until the end of next year; so my view is that METEORIC has no bearing on our choice to proceed with the GALACTIC data. And I would expect that well before METEORIC data are available to us, we will have worked out and settled on what we are going to do when it comes to the GALACTIC data.

Robert Blum

executive
#67

Alright. I appreciate everyone joining us on today's teleconference. Your ongoing backing and curiosity about Cytokinetics mean a lot. Clearly, we had an exceptionally hectic third quarter — whether you look at how far our pipeline moved forward, the agreements we got done, or, most rewardingly, the news that just came out about what GALACTIC showed. We're eager to reveal additional details about those findings at AHA and beyond; and we're grateful that you keep following everything we're up to. Operator, that being said, we're ready to wrap up the call now. Thank you.

Operator

operator
#68

Everyone, that brings us to the end of today's conference call. We appreciate your participation. You are welcome to disconnect at this time.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Cytokinetics, Incorporated transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Cytokinetics, Incorporated earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Cytokinetics, Incorporated or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.